Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022
March 03 2022 - 7:30AM
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or “the
Company”), a clinical stage biopharmaceutical company focused on
oncology and rare diseases, today announced it will host a virtual
R&D Day on Monday, March 14, 2022, to review the Company’s
alvelestat (MPH966) program. This will focus on the ongoing Phase 2
studies evaluating alvelestat in the treatment of alpha-1
antitrypsin deficiency (AATD)-related lung disease and provide
updates on the ongoing investigator sponsored Phase 1b/2 study in
patients with Bronchiolitis Obliterans (“BOS”) following
hematopoietic stem cell transplantation (“HCT”) and the Phase 1b/2
hospitalized COVID-19 trial. The event will feature key opinion
leaders and members of Mereo’s management team.
Alvelestat R&D Day
Information
Date: Monday, March 14, 2022
Time: 10:00 a.m. EST / 3:00 p.m. GMT
Presenters:
- Robert Stockley, MD, DSc, FRCP,
FERS, Professor of Medicine at the University Hospital Birmingham
(UK) and Director of the Lung Immunobiochemical Research Program at
the University Hospital Birmingham NHS Foundation Trust
- Steven Pavletic, MD, Clinical
Investigator and Head of the Graft versus-Host and Late Effects
Section in the Immune Deficiency Cellular Therapy Program of the
National Cancer Institute (NCI), National Institutes of Health
(NIH), Adjunct Professor of Medicine at the Georgetown University,
Lombardi Cancer Center, Division of Oncology
- Annie Im, MD, Associate Professor,
Division of Hematology/Oncology, University of Pittsburgh, UPMC
Hillman Cancer Center, Pittsburgh, PA
- Mike Wells, MD, MSPH, Associate
Professor of Medicine at the University of Alabama at Birmingham
(UAB)
- Denise Scots-Knight, PhD, Chief
Executive Officer
- John Lewicki, PhD, Chief Scientific
Officer
- Jacqueline Parkin, MB, BS;
PhD, Senior Vice President and Therapeutic Head
A live audio webcast of the R&D Day can be
accessed through the Investors section of the Company’s website
at www.mereobiopharma.com/investors. The event is expected to
last approximately two hours. An archived replay of the webcast
will be made available on the Company’s website.
About Mereo BioPharmaMereo
BioPharma is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to
improve outcomes for oncology and rare diseases. The Company has
developed a portfolio of six clinical stage product candidates.
Mereo’s lead oncology product candidate, etigilimab (anti-TIGIT),
has advanced into an open label Phase 1b/2 basket study evaluating
anti-TIGIT in combination with an anti-PD-1 in a range of tumor
types including three rare tumors and three gynecological
carcinomas, cervical, ovarian, and endometrial carcinomas. The
Company’s second oncology product, navicixizumab, for the treatment
of late line ovarian cancer, has completed a Phase 1 study and has
been partnered with OncXerna Therapeutics, Inc., formerly
Oncologie, Inc. The Company has two rare disease product
candidates, alvelestat for the treatment of severe Alpha-1
antitrypsin deficiency (AATD) and setrusumab for the treatment of
osteogenesis imperfecta (OI). Alvelestat has recently received U.S.
Orphan Drug Designation for the treatment of AATD and is being
investigated in an ongoing Phase 2 proof-of-concept study in the
U.S. and Europe, with top-line data expected in early Q2 2022. The
Company’s partner, Ultragenyx Pharmaceutical, Inc., is expected to
initiate a pivotal pediatric study for setrusumab in OI in H1
2022.
Forward-Looking StatementsThis
press release contains “forward-looking statements.” All statements
other than statements of historical fact contained in this press
release are forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the United States
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Forward-looking statements usually relate to future events and
anticipated revenues, earnings, cash flows or other aspects of our
operations or operating results. Forward-looking statements are
often identified by the words “believe,” “expect,” “anticipate,”
“plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,”
“estimate,” “outlook” and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company’s current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company’s forward-looking statements
involve known and unknown risks and uncertainties some of which are
significant or beyond its control and assumptions that could cause
actual results to differ materially from the Company’s historical
experience and its present expectations or projections. You should
carefully consider the foregoing factors and the other risks and
uncertainties that affect the Company’s business, including those
described in the “Risk Factors” section of its latest Annual Report
on Form 20-F, reports on Form 6-K and other documents furnished or
filed from time to time by the Company with the Securities and
Exchange Commission. The Company wishes to caution you not to place
undue reliance on any forward-looking statements, which speak only
as of the date hereof. The Company undertakes no obligation to
publicly update or revise any of our forward-looking statements
after the date they are made, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma Contacts: |
|
|
Mereo |
|
+44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer |
|
|
Christine Fox, Chief Financial Officer |
|
|
|
|
Burns McClellan (Investor Relations Adviser to
Mereo) |
|
+01 212 213 0006 |
Lee Roth |
|
|
Investors |
|
investors@mereobiopharma.com |
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Jul 2023 to Jul 2024